Introduction
Rapamycin, also called sirolimus, is a prescription medicine that inhibits part of the mechanistic target of rapamycin pathway. The abbreviation mTOR refers to a protein that helps cells respond to nutrients, hormones, energy availability and stress. It influences whether a cell prioritises growth and protein production or maintenance and recycling. (Review)
Rapamycin is one of the most extensively studied pharmacological interventions in experimental ageing biology. It has extended lifespan in multiple mouse studies, including studies that began treatment late in life. Human research has examined immune function, respiratory infections, physical performance, exercise responses, safety and selected healthspan measures, but no trial has demonstrated human lifespan extension. (Research, Review)
Rapamycin is not a precision epigenome editor. It does not direct a methylating, demethylating or histone-modifying enzyme to a selected gene. Its epigenetic effects occur indirectly through changes in nutrient sensing, metabolism, protein production, autophagy, cellular senescence and gene expression. (Review, Review)
The same pathway supports immune function, wound healing, glucose regulation, muscle adaptation and reproduction. Rapamycin must therefore be understood as a biologically powerful immunosuppressive medicine rather than simply an “anti-ageing drug.” Ageing and longevity are not FDA-approved indications. (FDA)
Informational only; no medical, dosing, or emergency instructions.
Quick Summary
- Rapamycin and sirolimus are names for the same active medicine. (FDA)
- mTOR is a nutrient- and growth-sensing protein kinase that regulates growth, metabolism, protein production and cellular recycling. (Review)
- mTOR operates mainly through two protein groups called mTORC1 and mTORC2. (Review)
- Rapamycin more directly inhibits mTORC1, although prolonged exposure can affect mTORC2 in some tissues. (Review)
- Rapamycin extended lifespan in genetically diverse mice even when treatment began late in life. (Research)
- Human trials have reported changes in vaccine responses, antiviral gene expression and selected infection outcomes. (Research, Research)
- Human evidence remains limited and has not demonstrated lifespan extension or whole-body rejuvenation. (Review)
- Rapamycin can influence epigenetic regulation indirectly but does not target a chosen DNA or histone mark. (Review)
- Available intervention evidence does not show a consistent rapamycin-related reduction across epigenetic clocks. (Review)
- Important prescription risks include infection, blood-cell abnormalities, lipid changes, mouth ulcers, impaired wound healing and medicine interactions. (FDA)
What It Is (Clinical Definition & Classification)
Rapamycin is a macrolide compound, meaning that its molecule contains a large ring-shaped structure. It was isolated from a microorganism and later developed as an immunosuppressive medicine. Its generic pharmaceutical name is sirolimus. (Review)
Rapamycin first binds a protein called FKBP12. The rapamycin–FKBP12 complex then binds mTOR and inhibits signalling from mTOR complex 1, abbreviated mTORC1. (Review)
A protein kinase is an enzyme that adds phosphate groups to other proteins, changing their activity. mTOR is a serine/threonine protein kinase and acts as a central controller of cellular growth and metabolism. (Review)
mTORC1
mTORC1 is a group of proteins built around mTOR. It responds to amino acids, insulin-related signals, cellular energy and stress. When active, it promotes protein and lipid production and suppresses important steps in autophagy. (Review)
mTORC2
mTORC2 is a second mTOR-containing protein complex. It influences cell survival, cytoskeletal organisation and aspects of glucose metabolism. Short-term rapamycin exposure mainly affects mTORC1, while prolonged exposure can interfere with mTORC2 assembly in some cells and tissues. (Review)
Rapalogs
Rapalogs are medicines related to rapamycin that affect the same pathway. Everolimus is one example used in human immune-ageing research. Rapalogs differ in formulation, approved use, distribution and pharmacology and should not be treated as interchangeable. (Research, Review)
Selective and catalytic mTOR inhibitors
Researchers are developing compounds intended to inhibit mTORC1 more selectively. Other agents inhibit the kinase’s catalytic site and may block both mTORC1 and mTORC2. The safety and ageing effects of these classes cannot be inferred directly from rapamycin. (Review)
Why It Happens (Causes & Risk Factors)
mTOR activity is necessary for normal life. During growth, immune responses, exercise recovery and wound healing, mTORC1 supports protein synthesis, cell proliferation and tissue rebuilding. The ageing hypothesis is that persistent growth signalling may become less useful later in life and contribute to reduced cellular maintenance. (Review)
This hypothesis is related to antagonistic pleiotropy. The term describes a biological programme that benefits survival or reproduction earlier in life but contributes to dysfunction when it remains active later. Persistent mTOR-driven growth is one proposed example. (Review)
mTOR activity changes in response to food intake, amino acids, insulin-related signals, exercise, illness, inflammation and tissue damage. It also differs among organs and cell types. Whole-body inhibition can therefore create beneficial effects in one context and harmful effects in another. (Review)
Mechanisms / Pathophysiology
Nutrient sensing
mTORC1 integrates information about amino acids, insulin-related signals, oxygen, energy and stress. High activity generally favours growth and biosynthesis—the construction of proteins, lipids and other cellular material. Lower activity can shift cellular priorities towards maintenance and recycling. (Review)
Autophagy
Autophagy literally means “self-eating.” It is a cellular recycling process that breaks down damaged proteins, worn-out organelles and other material so that their components can be reused or removed. Active mTORC1 suppresses important autophagy steps, while mTORC1 inhibition can permit more autophagic activity. (Review)
Autophagy is not automatically beneficial at every level. Its effects depend on tissue, timing and disease context, and excessive or poorly controlled recycling can also interfere with normal cell function. (Review)
Cellular senescence
A senescent cell is a cell that has entered a durable state in which it no longer divides normally. Some senescent cells release inflammatory and tissue-modifying signals. Persistent mTORC1 signalling contributes to several features of cellular senescence. (Research)
The senescence-associated secretory phenotype, abbreviated SASP, is the mixture of inflammatory proteins and signalling molecules released by some senescent cells. Rapamycin may suppress parts of the SASP, but suppressing secretions is not the same as removing the cell or restoring youthful identity. (Research)
Protein synthesis and proteostasis
Proteostasis means maintaining a workable balance among protein production, folding, repair and disposal. mTORC1 stimulates protein production through downstream proteins including S6 kinase and 4E-BPs. Lower mTORC1 signalling may reduce unnecessary protein production and shift resources towards maintenance. (Review)
Epigenetic regulation
Rapamycin can change transcription and chromatin-related processes indirectly by altering metabolism, protein production, autophagy and transcription-factor activity. It does not direct an epigenetic enzyme to a selected DNA sequence. (Review)
Animal evidence suggests that rapamycin can slow or prevent a portion of age-associated DNA-methylation changes. DNA methylation is the attachment of small methyl groups to DNA and can influence nearby gene activity. These animal findings do not establish equivalent human epigenetic rejuvenation. (Review, Research)
Immune ageing
Immunosenescence means age-related changes in immune function, including weaker responses to some infections and vaccines. Human trials have examined whether partial mTOR inhibition can improve selected immune responses without producing the level of immunosuppression used in transplantation. (Research)
Symptoms, Patterns, and Differential Clues
High mTOR activity is not a symptom-defined diagnosis. It cannot be identified from fatigue, weight change, muscle soreness or a consumer biological-age test. mTOR signalling fluctuates with eating, exercise, illness, sleep and tissue repair. (Review)
Drug-related effects also should not be interpreted as evidence that ageing is being reversed. Mouth ulcers, infections, blood-cell abnormalities, increased blood lipids or delayed healing can be adverse effects of sirolimus rather than signs of beneficial pathway adjustment. (FDA)
Evaluation & Diagnosis (Clinical Context)
There is no validated clinical test showing that a healthy individual has “excess mTOR” or needs rapamycin for ageing. Human trials use defined measures such as vaccine responses, infection counts, physical performance, cognitive tests, blood measurements and adverse events. (Research, Research)
An epigenetic clock is a mathematical model that estimates an age-related characteristic from DNA-methylation measurements. A non-human-primate study assessed rapamycin using marmoset clocks, while a later intervention review reported no detectable rapamycin effect in the next-generation clock evidence it evaluated. These are biomarker findings rather than proof of functional rejuvenation. (Research, Review)
A credible human ageing study would need to assess multiple dimensions, including functional outcomes, disease incidence, immune competence, metabolic effects, adverse events and durability. Lifespan evidence would require long follow-up and cannot be replaced by one molecular biomarker. (Review)
Treatment Options Snapshot (Evidence-Graded, Descriptive Only)
Prescription / Medical Therapies
- Sirolimus for approved medical indications — Sirolimus is used in defined medical settings, including prevention of kidney-transplant rejection and treatment of lymphangioleiomyomatosis. Outcomes apply to those medical indications and do not establish anti-ageing efficacy. Evidence: Strong for approved indications. (FDA)
- Everolimus and related rapalogs — Short-term trials in older adults reported changes in influenza-vaccine response and immune-gene expression. These findings do not establish lifespan extension and cannot be assigned automatically to sirolimus. Evidence: Limited-Mixed for ageing-related outcomes. (Research)
- Selective TORC1 inhibitors — Randomized trials measured antiviral gene expression, respiratory-infection rates and illness severity. Molecular effects were observed, but clinical outcomes varied across trials and populations. Evidence: Limited-Mixed. (Research, Research)
- Intermittent sirolimus in healthy-ageing research — Small studies and a longer 2025 trial assessed safety, adverse events and selected healthspan measures. Human lifespan extension and a favourable long-term risk–benefit balance have not been established. Evidence: Emerging. (Research, Research)
- Sirolimus combined with exercise — A randomized older-adult study measured muscle strength and endurance responses during an exercise programme. The study addressed short-term physical adaptation rather than lifespan or epigenetic rejuvenation. Evidence: Emerging. (Research)
Supplements / Vitamins (Research Context Only)
Available direct human supplement evidence was more limited than the evidence available for prescription mTOR inhibitors.
No supplement has demonstrated the same selective and clinically characterised mTORC1 inhibition as rapamycin.
Tier A — Strong / Moderate Evidence
No supplement met Strong or Moderate criteria as a rapamycin substitute for human ageing.
Tier B — Limited-Mixed Evidence
- Spermidine — Human studies have measured cognitive, cardiovascular and ageing-related outcomes, while laboratory evidence connects spermidine with autophagy. Human findings remain mixed, and spermidine does not reproduce clinically measured rapamycin exposure. Evidence: Limited-Mixed. (Review)
- Resveratrol — Human trials have evaluated glucose, lipid, vascular and inflammatory measures related to nutrient-sensing pathways. Results vary by population and formulation, and resveratrol is not a demonstrated mTORC1-selective geroprotector. Evidence: Limited-Mixed. (Review)
- Berberine — Human disease studies report changes in glycaemic and lipid outcomes, while laboratory research connects the compound with AMPK–mTOR signalling. Disease-specific metabolic findings do not establish rapamycin-like anti-ageing effects. Evidence: Limited-Mixed. (Review)
- Omega-3 fatty acids — Human trials have assessed cardiovascular, inflammatory and epigenetic-clock outcomes. These effects do not demonstrate selective mTORC1 inhibition, and clock findings are not evidence of rejuvenation. Evidence: Limited-Mixed. (Review)
Tier C — Emerging Evidence
- NMN and nicotinamide riboside — Human studies have measured NAD⁺-related metabolites and selected metabolic or functional outcomes. These compounds act through NAD⁺ biology rather than direct mTORC1 inhibition and have not produced rapamycin-like human longevity evidence. Evidence: Emerging. (Review)
- Alpha-ketoglutarate — Human research has measured DNA-methylation-age estimates and metabolic outcomes. AKG is connected to demethylating enzymes rather than selective mTORC1 inhibition, and clinical rejuvenation remains unproven. Evidence: Emerging. (Review)
- Fisetin and quercetin — These flavonoids are investigated mainly through senescence, inflammation and senolytic hypotheses. Senescence-related activity does not make them mTOR inhibitors or substitutes for rapamycin. Evidence: Emerging. (Review)
- Urolithin A — Human trials have measured mitochondrial and muscle-related biomarkers. Its proposed mitophagy effects are distinct from pharmacological mTORC1 inhibition. Evidence: Emerging. (Review)
- GlyNAC — Small older-adult studies have assessed glutathione, oxidative-stress and physical-function measures. These redox outcomes do not establish mTOR inhibition or rapamycin-like geroprotection. Evidence: Emerging. (Review)
Topical / Cosmetic Ingredients (Research Context Only)
Available direct human topical/local evidence was limited for this topic.
- Topical rapamycin — Small human skin studies have measured senescence-associated markers and local skin-appearance outcomes. Local findings do not establish systemic mTOR modulation, lifespan extension or epigenetic rejuvenation. Evidence: Emerging. (Review)
Dietary Sources (Research Context Only)
Direct human dietary-source evidence was narrower than the target item count.
- Caloric restriction — Human studies measure metabolic, inflammatory and ageing-related biomarkers, and reduced energy intake can lower nutrient signalling. Rapamycin and caloric restriction overlap partly but do not act through identical pathways. Evidence: Moderate for selected metabolic outcomes; Limited-Mixed for ageing modification. (Review, Review)
- Intermittent fasting — Human studies assess weight, glucose and metabolic outcomes. Fasting can affect AMPK, sirtuins and mTOR-related signalling, but results depend on the protocol and do not establish pharmacological mTORC1 inhibition. Evidence: Limited-Mixed. (Review)
- Protein and amino-acid restriction — Reduced protein or selected amino-acid intake can lower nutrient signals entering mTORC1. Long-term human evidence for lifespan or broad ageing outcomes remains insufficient, and restriction may carry different trade-offs in older adults vulnerable to muscle loss. Evidence: Emerging. (Review)
- Mediterranean-style dietary patterns — Human trials support selected cardiometabolic outcomes, but the effects cannot be assigned specifically to mTOR inhibition. Evidence: Moderate for cardiometabolic health; Emerging for mTOR-specific ageing claims. (Review)
What Research Has Studied
- Median and maximal lifespan in genetically diverse mice. (Research, Research)
- Cancer, cardiac, neurological, immune and metabolic outcomes in mouse ageing models. (Review)
- Influenza-vaccine response in older adults. (Research)
- Antiviral gene expression and respiratory-infection outcomes. (Research, Research)
- Physical performance and cognition in small older-adult trials. (Research)
- Muscle strength and adaptation during exercise. (Research)
- DNA-methylation age in marmosets. (Research)
- Epigenetic-clock responses across intervention studies. (Review)
- Infection, blood counts, lipids, glucose, mouth ulcers, lung effects and wound healing. (FDA)
Safety, Interactions & Regulatory Context
Sirolimus is an immunosuppressive prescription medicine. FDA-approved indications include prevention of kidney-transplant rejection and treatment of lymphangioleiomyomatosis, a rare lung disease. Ageing and longevity are not approved indications. (FDA)
The FDA label warns about increased susceptibility to infection and possible malignancy associated with immunosuppression. Other concerns include blood-cell abnormalities, elevated blood lipids, mouth ulcers, impaired wound healing, lung toxicity and interactions with medicines that change sirolimus metabolism. (FDA)
mTORC1 supports muscle-protein production and tissue repair. Inhibition during exercise, injury or recovery may therefore have different consequences from inhibition during periods of low anabolic demand. Anabolic means related to building tissue or molecules. Human exercise studies remain exploratory. (Research)
Intermittent or lower-exposure strategies are intended to reduce continuous pathway inhibition. Early tolerability findings do not prove that intermittent treatment prevents long-term infection, metabolic, reproductive or wound-healing risks. (Research, FDA)
Evidence Overview
Rapamycin has unusually strong animal evidence for a pharmacological ageing intervention. Multiple studies in genetically diverse mice have reported increased median or maximal lifespan, including studies beginning treatment late in life. (Research, Research)
Human evidence remains much narrower. Short-term trials have reported changes in influenza-vaccine response, antiviral gene expression and selected respiratory-infection outcomes. Other research has focused on safety, physical function, exercise responses and healthspan measures. No human trial has demonstrated lifespan extension. (Research, Research, Review)
Rapamycin’s relationship with epigenetics is indirect. Animal evidence suggests that it can modify some age-associated DNA-methylation patterns, but available intervention reviews do not show a consistent human epigenetic-clock rejuvenation signal. (Review, Review)
The central translational problem is balancing maintenance against necessary growth. Researchers aim to reduce harmful late-life mTORC1 activity without impairing immune defence, wound healing, muscle adaptation, glucose regulation or other essential processes. More selective inhibitors and intermittent exposure are being studied, but neither approach is established as a safe human anti-ageing treatment. (Review)
Supplements and diets can influence pathways that communicate with mTOR. None has demonstrated pharmacological equivalence to rapamycin, and overlapping mechanisms do not prove additive benefit when interventions are combined. (Review)
Evidence Confidence Classification
Overall Rating: Limited-Mixed
Rapamycin has strong and reproducible animal lifespan evidence. Human ageing evidence consists of relatively small, short or heterogeneous trials involving immune, infection, safety and functional outcomes. Human lifespan extension, durable epigenetic rejuvenation and a favourable long-term risk–benefit balance have not been established. (Review, Review)
What Does Not (Evidence Gaps)
- Mouse lifespan extension as proof of human longevity — Rapamycin increases lifespan in several mouse studies, but species differences and clinical safety constraints prevent direct translation. (Research)
- Improved vaccine response as proof of whole-body rejuvenation — A vaccine response is a specific immune outcome and does not establish systemic age reversal. (Research)
- Rapamycin as a direct epigenome editor — Rapamycin changes signalling and downstream transcription rather than targeting a selected DNA or histone mark. (Review)
- A lower epigenetic-clock value as proof of clinical benefit — Clock evidence is inconsistent, and biomarker change does not establish improved function, disease risk or survival. (Review)
- Supplements as equivalent to rapamycin — No supplement has demonstrated the same selective, clinically measurable mTORC1 inhibition and human ageing outcomes. (Review)
- Greater mTOR inhibition as automatically better — mTOR supports immune, metabolic, repair and muscle functions, so excessive or poorly timed inhibition can be harmful. (FDA)
FAQ
1. What is rapamycin?
Rapamycin is an mTOR-inhibiting prescription medicine also known as sirolimus. It has approved medical uses but is not approved as a treatment for ageing. (FDA)
2. What does mTOR mean?
mTOR means mechanistic target of rapamycin. It is a protein kinase that helps cells respond to nutrients, hormones, energy and stress. (Review)
3. What is the difference between mTORC1 and mTORC2?
mTORC1 strongly regulates growth, protein production and autophagy. mTORC2 influences cell survival, internal cell structure and parts of glucose metabolism. (Review)
4. Does rapamycin directly edit DNA?
No. Rapamycin changes cellular signalling and downstream gene activity but does not alter DNA sequence or target a selected epigenetic site. (Review)
5. What is autophagy?
Autophagy is a cellular recycling process that breaks down damaged proteins and cell components. mTORC1 inhibition can permit greater autophagic activity. (Review)
6. Has rapamycin extended lifespan in animals?
Yes. Rapamycin has extended lifespan in multiple mouse studies, including when treatment began late in life. (Research)
7. Has rapamycin extended human lifespan?
No human trial has demonstrated lifespan extension. Human research has measured immune, infection, safety and functional outcomes instead. (Review)
8. Why did an mTOR inhibitor improve vaccine response?
Partial mTOR inhibition altered immune-cell and gene-expression responses in older adults. The finding was specific to the studied population, compound and vaccine and does not prove general rejuvenation. (Research)
9. Is rapamycin an immunosuppressant?
Yes. In approved clinical use it can reduce immune activity and is used in transplant medicine. Experimental ageing studies have investigated different exposures, but long-term safety remains uncertain. (FDA)
10. What is a rapalog?
A rapalog is a medicine related to rapamycin that acts on the same pathway. Everolimus is one example studied in older-adult immune research. (Research)
11. Is rapamycin a caloric-restriction mimetic?
Rapamycin and caloric restriction share some effects on nutrient signalling, but their mechanisms are not identical. A mimetic is something intended to reproduce part of another intervention’s biological effect. (Review)
12. Does rapamycin reverse epigenetic age?
Animal methylation research suggests possible effects, but intervention reviews do not show a consistent human epigenetic-clock reduction. (Research, Review)
13. Does rapamycin remove senescent cells?
No. Rapamycin may suppress parts of the SASP, but it is not generally classified as a senolytic that removes senescent cells. (Research)
14. Are NMN or spermidine substitutes for rapamycin?
No. They affect different biological pathways and have not demonstrated equivalent mTORC1 inhibition or human lifespan effects. (Review)
15. Can fasting reproduce rapamycin?
Fasting can alter nutrient and mTOR-related signalling, but it does not reproduce rapamycin’s pharmacology, tissue distribution or safety profile. (Review)
16. Why can mTOR inhibition affect muscle?
mTORC1 supports muscle-protein production and adaptation to exercise. Inhibition may therefore interact with training, recovery and muscle maintenance. (Research)
17. What are the principal safety concerns?
Important concerns include infection, mouth ulcers, blood-cell changes, elevated lipids, metabolic effects, lung toxicity, impaired healing and medicine interactions. (FDA)
18. Is intermittent rapamycin proven safer?
Intermittent schedules are intended to avoid continuous pathway inhibition, and early studies report relative tolerability. Long-term comparative safety and anti-ageing benefit remain unestablished. (Research)
19. Why are selective mTORC1 inhibitors being developed?
Researchers hope to preserve useful mTORC1-related effects while reducing disruption of mTORC2 and other necessary functions. Whether newer agents improve long-term safety or healthspan remains under study. (Review)
20. What would show that rapamycin slows human ageing?
Evidence would need to demonstrate reproducible improvements in meaningful health or functional outcomes, acceptable long-term safety and ideally reduced incidence of several age-related diseases or mortality. Molecular biomarkers or immune changes alone would be insufficient. (Review)
Resources
Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice — Research — https://pubmed.ncbi.nlm.nih.gov/19587680/
Rapamycin-Mediated Lifespan Increase in Mice Is Dose and Sex Dependent — Research — https://pubmed.ncbi.nlm.nih.gov/24341993/
mTOR as Regulator of Lifespan, Ageing and Cellular Senescence — Review — https://pubmed.ncbi.nlm.nih.gov/29190625/
Effect of Rapamycin on Ageing and Age-Related Diseases — Review — https://pubmed.ncbi.nlm.nih.gov/33037985/
mTOR Inhibition Improves Immune Function in Older Adults — Research — https://pubmed.ncbi.nlm.nih.gov/25540326/
TORC1 Inhibition Enhances Immune Function and Reduces Infections — Research — https://pubmed.ncbi.nlm.nih.gov/29997249/
Targeting the Biology of Ageing With mTOR Inhibitors — Research — https://pubmed.ncbi.nlm.nih.gov/33977284/
Rapamycin Feasibility and Safety in an Older Cohort — Research — https://pubmed.ncbi.nlm.nih.gov/29408453/
Weekly Sirolimus and Exercise in Older Adults — Research — https://pubmed.ncbi.nlm.nih.gov/39354527/
PEARL Rapamycin Safety and Healthspan Trial — Research — https://pubmed.ncbi.nlm.nih.gov/40188830/
DNA-Methylation Age Analysis of Rapamycin in Marmosets — Research — https://pubmed.ncbi.nlm.nih.gov/34482522/
Interventions Affecting Next-Generation Epigenetic Clocks — Review — https://pubmed.ncbi.nlm.nih.gov/42294499/
Persistent mTORC1 Signalling in Cellular Senescence — Research — https://pubmed.ncbi.nlm.nih.gov/28566325/
Rapamycin: One Drug, Many Effects — Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC3972801/
Targeting the Biology of Ageing With mTOR Inhibitors — Review — https://pubmed.ncbi.nlm.nih.gov/37142830/
mTOR and Ageing — Review — https://pubmed.ncbi.nlm.nih.gov/31174250/
An InhibiTOR of Ageing Emerges From Easter Island — Review — https://pubmed.ncbi.nlm.nih.gov/27208895/
Is Rapamycin a Dietary-Restriction Mimetic? — Review — https://pubmed.ncbi.nlm.nih.gov/30854544/
mTOR, Autophagy and Antagonistic Pleiotropy — Review — https://pubmed.ncbi.nlm.nih.gov/31572724/
The Role of DNA Methylation in the Epigenetics of Ageing — Review — https://pubmed.ncbi.nlm.nih.gov/30419258/
Lifespan-Extending Interventions and Mouse DNA Methylation — Research — https://pubmed.ncbi.nlm.nih.gov/28351383/
Healthspan Interventions Targeting Fundamental Ageing Processes — Review — https://pubmed.ncbi.nlm.nih.gov/33155651/
Dietary and Pharmacological Modulation of Human Epigenetic Ageing — Review — https://pubmed.ncbi.nlm.nih.gov/41096907/
Clinical Evidence for Off-Label Rapamycin in Healthy Adults — Review — https://pubmed.ncbi.nlm.nih.gov/40778880/
Rapamune Prescribing Information — FDA — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070%2C021110s087s088lbl.pdf
More from the Medical & Health Conditions Encyclopedia
